BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease. The company is headquartered in San Carlos, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-4.19M |
| EBITDA | $-7.38M |
| Operating Margin | 0.00% |
| Return on Equity | -1803.00% |
| Return on Assets | -135.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.18 |
| Price-to-Book | 5.89 |
| Price-to-Sales (TTM) | 2520.59 |
| EV/Revenue | 23.81 |
| EV/EBITDA | -3.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $15.14M |
| Float | $12.26M |
| % Insiders | 17.91% |
| % Institutions | 14.79% |
Volatility is currently expanding
SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term milestones.
SUNNYVALE, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Peter Altman, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026.
SUNNYVALE, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces receipt of FDA confirmation of the outcome of its Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System (Helix).
BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript
SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the second quarter of 2026 by conference call on Wednesday, August 12, 2026 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session.
LUNR, GLDG and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2026.
AZ, AISP and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 14th, 2026.
SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the Company's Chief Executive Officer, Peter Altman, issued the following letter to shareholders.
SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced receipt of FDA minutes from its Q-Sub Meeting with FDA Center for Biologics Evaluation and Research (CBER) on the CardiAMP Cell Therapy System for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF).
– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development – Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted all available treatment options SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the oral presentation of the results of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial (CardiAMP CMI) preliminary open label cohort at EuroPCR, a leading interventional cardiovascular medicine conference held in Paris.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BCDA and any ticker you trade — then tracks every position and per-strategy win rate.
